Business
NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team
- Upon closing its IPO the company appointed four new board members. Dr. Ferenc Tracik joined the company's senior management as Chief Scientific Officer.
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"- Upon closing its IPO the company appointed four new board members. Dr. Ferenc Tracik joined the company's senior management as Chief Scientific Officer.\n\n\nCAMBRIDGE, Mass., Dec. 21, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the appointment of four new directors upon the closing of the company's recent IPO. The new directors will join the current directors, Mark Leuchtenberger, Chairman of the Board, and Alon Ben-Noon, the CEO and founder.\n\n \n \n \n \n \n \n\n \nThe new directors bring a diverse set of experiences in healthcare and the biotechnology industry that will be instrumental for guiding NeuroSense through the development and commercialization of its product portfolio. Joining the NeuroSense board are: \nYael German, a former Israeli Member of Knesset and former Minister of Health; Caren Deardorf, currently Chief Commercial Officer at Magenta Therapeutics, who previously led multiple global launches across rare disease and neurology at Biogen Inc.; Christine Pellizzari, currently Chief Legal Officer at Science 37 and a veteran of several rare disease focused biotech companies in similar roles; and Cary Claiborne, currently Chief Operating Officer and board member at Adial Pharmaceuticals and the founder and CEO of Prosperity Capital Management, LLC. Ms. Pellizzari will chair the Compensation Committee and Mr. Claiborne, with extensive experience as the CFO of several biotech companies, will chair the Audit Committee. \nAs the company previously announced, since October 1, 2021 Mark Leuchtenberg serves as the Chairman of the Board . Mr. Leuchtenberger has over 25 years of experience as a senior executive in the biopharmaceutical industry where he has led companies through private financings and initial public offerings, taken products from IND through to commercialization and achieved M&A exits and served as a President, Chief Executive Officer and a board member at several publicly traded companies.\nIn addition to the new board appointments, the company is pleased to announce that Dr. Ferenc Tracik, a neurologist with significant scientific and management experience in developing neurodegenerative therapies with companies such as Biogen, Novar...